Compare BRBS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | MYGN |
|---|---|---|
| Founded | 1893 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 327.1M |
| IPO Year | 2015 | 1996 |
| Metric | BRBS | MYGN |
|---|---|---|
| Price | $4.01 | $3.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $7.64 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $111,284,000.00 | ★ $771,400,000.00 |
| Revenue This Year | N/A | $6.86 |
| Revenue Next Year | N/A | $5.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.99 | 2.33 |
| 52 Week Low | $3.23 | $2.74 |
| 52 Week High | $4.79 | $8.59 |
| Indicator | BRBS | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.14 | 59.37 |
| Support Level | $3.88 | $3.53 |
| Resistance Level | $4.08 | $5.42 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 64.06 | 96.67 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.